Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?

AIDS

Volumn 24, Issue 5, 2010, Pages 775-776

  Wagner, Bradley G ^a   Kahn, James S ^b   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; DRUG UTILIZATION; EPIDEMIC; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LABORATORY TEST; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TRANSMISSION;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EPIDEMICS; HIV INFECTIONS; HUMANS; MASS SCREENING;

EID: 77949368491     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283366782     Document Type: Note

References (10)

1. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al. When to start antiretrovial therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
2. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654.
3. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493.
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
5. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'Test and Treat' in hyper-endemic settings. AIDS 2010; 24:729-735.
6. Kitahata MM, Gange SJ, Abraham AG, Meriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
7. Emery S, Neuhaus JA, Philips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
8. Sterne JA, May M, Costagliola D, de Wolf F, Philips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1 infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363
9. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector-progress report 2008. http:// www.who.int/hiv/pub/towards- universal-access-report-2008. pdf.
10. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an anti-retroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.